Scott Gottlieb

Food and Drug Administration

Rock-Bottom Drug Prices For Older Generic Drugs Contribute To Worsening Shortages, FDA Says | Kaiser Health News | 10/30/2019

… factors, according to a federal report published on Tuesday. The report, the work of a task force led by the Food and Drug Administration and comprising representatives from various federal agencies, recommended that buyers like … a private investor, former U.S. Food and Drug Administration Commissioner Scott Gottlieb is focused on an area where few have found success in recent years: developing new antibiotics. Since leaving the FDA in April, Gottlieb …

Follow Scott Gottlieb:    

Tempus Announces the Appointment of Scott Gottlieb, MD, to Its Board of Directors | Globe Newswire | 10/29/2019

… Scott Gottlieb, MD, has joined its Board of Directors. Dr. Gottlieb will serve as an advisor to Tempus and its leadership team, leveraging his vast experience as a medical policy expert and public health advocate to support Tempus as it harnesses the power and promise of big data and artificial intelligence to personalize patient care. Dr. Gottlieb most recently served as the 23 rd Commissioner of the Food and Drug …

Ex-FDA chief Gottlieb sees investment opportunity in ‘unloved’ antibiotics | Yahoo News | 10/29/2019

As a private investor, former U.S. Food and Drug Administration Commissioner Scott Gottlieb is focused on an area where few have found success in recent years: developing new antibiotics.” data-reactid=”23” NEW YORK (Reuters) - As a private investor, former U.S. Food and Drug Administration Commissioner Scott Gottlieb is focused on an area where few have found success in recent years: developing new antibiotics. Since leaving the FDA in April …

Pfizer

Rock-Bottom Drug Prices For Older Generic Drugs Contribute To Worsening Shortages, FDA Says | Kaiser Health News | 10/30/2019

… FDA Chief Gottlieb Sees Investment Opportunity In ‘Unloved’ Antibiotics As a private investor, former U.S. Food and Drug Administration Commissioner Scott Gottlieb is focused on an area where few have found success in recent years … to the left, sources say. (Sullivan, 10/30) The Associated Press: Pfizer Narrows Its Focus And Profit Soars In 3Q Pfizer’s third-quarter profit nearly doubled after it booked an $8.1 billion gain on paper by …

Chutes & Ladders—Pfizer Chairman Read heading for the exit | FierceBiotech | 10/4/2019

… the bad—from your shop to Kyle Blankenship , and we will feature it here at the end of each week. Pfizer’s Read to retire at year’s end, handing chairmanship to CEO Bourla Pfizer Chairman Ian … now identified Hahn as the most likely person to replace Scott Gottlieb as the next permanent commissioner of the FDA. Early last month, Politico Pro named Hahn as the “clear frontrunner,” adding that he was …

New Enterprise Associates

Rock-Bottom Drug Prices For Older Generic Drugs Contribute To Worsening Shortages, FDA Says | Kaiser Health News | 10/30/2019

Scott Gottlieb is focused on an area where few have found success in recent years: developing new antibiotics. Since leaving the FDA in April, Gottlieb has revealed little about what types of investments he would make in his new role at New Enterprise Associates, one of the country’s largest venture capital firms where he worked prior to his time in government. (Spalding, 10/29) The Hill: House Democrats Clash Over Pelosi’s …

Ex-FDA chief Gottlieb sees investment opportunity in ‘unloved’ antibiotics | Yahoo News | 10/29/2019

As a private investor, former U.S. Food and Drug Administration Commissioner Scott Gottlieb is focused on an area where few have found success in recent years: developing new antibiotics.” data-reactid=”23” NEW YORK (Reuters … of investments he would make in his new role at New Enterprise Associates, one of the country’s largest venture capital firms where he worked prior to his time in government. But in an interview, Gottlieb …

Scott Gottlieb joins Ateon’s board, Jonathan Bush named executive chairman of Firefly, and more digital health hires and departures | MobiHealthNews | 9/19/2019

… up as GM and SVP of Fitbit Health; Cala Health appoints Renee Ryan as CEO; Craig Maloney joins Maestro Health. Scott Gottlieb joins Ateon’s board, Jonathan Bush named executive chairman of Firefly, and more digital … include roles with nonprofit drug development group FasterCures, Pfizer and New Enterprise Associates. Former general manager of Fitbit Health Solutions Adam Pellegrini has departed the wearables maker in favor of a new role as SVP …

Medicare

Rock-Bottom Drug Prices For Older Generic Drugs Contribute To Worsening Shortages, FDA Says | Kaiser Health News | 10/30/2019

… FDA Chief Gottlieb Sees Investment Opportunity In ‘Unloved’ Antibiotics As a private investor, former U.S. Food and Drug Administration Commissioner Scott Gottlieb is focused on an area where few have found success in recent years … preempted by the federal Employee Retirement Income Security Act and Medicare Part D regulations, the PCMA argued in an Oct. 25 lawsuit. (Wille, 10/28) Bloomberg Law: Illinois Ends Protracted Drug Pricing Case With $248 Million …

Tempus Announces the Appointment of Scott Gottlieb, MD, to Its Board of Directors | Globe Newswire | 10/29/2019

… Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Dr. Scott Gottlieb, MD, has joined its Board of Directors. Dr. Gottlieb will serve as an … a Senior Advisor to the Administrator of the Centers for Medicare and Medicaid Services, Dr. Gottlieb worked on the implementation of the Medicare drug benefit, where he supported policy work on quality improvement and the …

Ukraine dishonesty blitz: Trump made 66 false claims last week - CNNPolitics | 10/9/2019

… false claims were related to the Ukraine scandal. Trump made 20 false claims on Twitter, 11 in a speech on Medicare at The Villages retirement community in Florida, and 10 in an exchange with reporters … access experimental medications – but the government almost always said yes. Scott Gottlieb, who served as Trump’s FDA commissioner until April, told Congress in 2017 that the FDA had approved 99% of patient requests. “Emergency requests …

Biotech

Rock-Bottom Drug Prices For Older Generic Drugs Contribute To Worsening Shortages, FDA Says | Kaiser Health News | 10/30/2019

… FDA Chief Gottlieb Sees Investment Opportunity In ‘Unloved’ Antibiotics As a private investor, former U.S. Food and Drug Administration Commissioner Scott Gottlieb is focused on an area where few have found success in recent years … Former Axovant CEO David Hung Is Back — Leading A Cancer Biotech With Hefty Funding The company, Nuvation Bio, aims to be ambitious — according to the press release announcing the round, it has seven “mechanistically distinct …

Proteomics and the promise of ‘enriching’ clinical trials | 10/29/2019

… till now, though, the technology has been underutilised in other areas – not least clinical trials. In March, outgoing FDA commissioner Scott Gottlieb stated that modernising clinical trials was a priority for the FDA, remarking that … We work with many of the most innovative pharma and biotech companies, who use our discovery proteomics services to advance their early-stage research programs. We increasingly see an interest in using our technology further …

Chutes & Ladders—Pfizer Chairman Read heading for the exit | FierceBiotech | 10/4/2019

Scott Gottlieb as the next permanent commissioner of the FDA. Early last month, Politico Pro named Hahn as the “clear frontrunner,” adding that he was the only one of the three finalists to meet with Trump in person. FierceBiotech After major Alzheimer’s flops, Biogen’s R&D chief Ehlers hits the exit Biogen R&D head Michael Ehlers , M.D., Ph.D., is out. Troubled Big Biotech Biogen is losing R&D head …

Medicaid

Rock-Bottom Drug Prices For Older Generic Drugs Contribute To Worsening Shortages, FDA Says | Kaiser Health News | 10/30/2019

… FDA Chief Gottlieb Sees Investment Opportunity In ‘Unloved’ Antibiotics As a private investor, former U.S. Food and Drug Administration Commissioner Scott Gottlieb is focused on an area where few have found success in recent years … to settle allegations they manipulated wholesale prices to increase their Medicaid reimbursements, Illinois Attorney General Kwame Raoul (D) said Oct. 28. The settlement brings to $678 million the amount Illinois has been able to recover …

Tempus Announces the Appointment of Scott Gottlieb, MD, to Its Board of Directors | Globe Newswire | 10/29/2019

… Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, today announced that Dr. Scott Gottlieb, MD, has joined its Board of Directors. Dr. Gottlieb will serve as an … Advisor to the Administrator of the Centers for Medicare and Medicaid Services, Dr. Gottlieb worked on the implementation of the Medicare drug benefit, where he supported policy work on quality improvement and the agency’s coverage …

Next Steps For Netflix: Can ‘All You Can Treat’ Contracts Work Beyond Hepatitis C? | Health Affairs | 9/25/2019

Medicaid programs generally pursue subscription-style agreements with HCV drug manufacturers. Now the states of Louisiana and Washington , with Gilead and AbbVie respectively, are pursuing Netflix-type contracts for Hepatitis C treatments. Policy analysts are citing the Netflix model as potentially applicable to other therapeutic areas. The United Kingdom’s national health service has proposed the idea of subscription financing for antibiotics. Scott Gottlieb, former Commissioner of the Food and Drug …

Express Scripts

Rock-Bottom Drug Prices For Older Generic Drugs Contribute To Worsening Shortages, FDA Says | Kaiser Health News | 10/30/2019

… FDA Chief Gottlieb Sees Investment Opportunity In ‘Unloved’ Antibiotics As a private investor, former U.S. Food and Drug Administration Commissioner Scott Gottlieb is focused on an area where few have found success in recent years … which is aimed at curbing controversial practices by PBMs like Express Scripts and CVS Health, is preempted by the federal Employee Retirement Income Security Act and Medicare Part D regulations, the PCMA argued in an …

Gene therapy coming of age: Opportunities and challenges to getting ahead | 10/2/2019

… grow significantly, with ten to 20 cell and gene therapy approvals per year over the next five years. 4 4. Scott Gottlieb, “Statement from FDA Commissioner Scott Gottlieb, M.D. and Peter Marks, M.D., Ph.D., Director … on costs of drugs, hospitalization, and other associated expenses. See Express Scripts 2015: drug trend report , Express Scripts Lab, March 2016, lab.express-scripts. com; and D.R. Globe, R.G. Curtis, M.A. Koerper, HUGS Steering Committee, “Utilization …

CNBC’s 2019 Healthy Returns Summit: Full Panels | 5/23/2019

… from some of the most influential leaders in health care. Speakers included United Therapeutics CEO Martine Rothblatt, Former FDA Commissioner Scott Gottlieb, Novartis CEO Vasant Narasimhan, Cigna CEO David Cordani, Johnson & Johnson CEO Alex Gorsky … health crisis. VIDEO 31:55 31:55 New Combinations: Cigna CEO and Express Scripts and Cigna Services president at Healthy Returns Healthy Returns When Cigna closed its $54 billion deal in December to buy Express Scripts, it …